Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study.

Authors

Fasiha Kanwal, Camden Lopez, Jing Ning, Michelle Luster, K Rajender Reddy, Neehar D Parikh, Amit G Singal, Jorge A Marrero, Jagpreet Chhatwal, Ziding Feng, Stephanie Page-Lester, Eugene J Koay, Hashem B El-Serag

Published in

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Feb 09, 2026. Epub Feb 09, 2026.

Abstract

We previously developed a hepatocellular carcinoma (HCC) risk stratification model, the Texas HCC Consortium Risk Index (THCC-RI), for patients with cirrhosis. In this cohort study, we aimed to externally validate THCC-RI in a prospective cohort of patients with cirrhosis.
We used data from the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study, a prospective cohort of patients with cirrhosis enrolled in regular HCC surveillance at 7 centers in the United States. Patients were followed from enrollment until HCC diagnosis, liver transplantation, death, or December 2023.
The analysis was conducted in 1560 patients who contributed a total of 5051 person-years of follow-up (mean age, 59 years; 47% women; 40% with hepatitis C; 16% alcohol-associated disease; and 22% metabolic dysfunction-associated steatotic liver disease). Over a median follow-up of 2.5 years, 114 patients developed HCC. The THCC-RI had a C-index of 0.77 (95% confidence interval [CI], 0.64-0.85), with area under the receiver operating characteristic curve estimates of 0.77 (95% CI, 0.65-0.85) at 1 year, 0.73 (95% CI, 0.66-0.79) at 3 years, and 0.71 (95% CI, 0.65-0.77) at 5 years. THCC-RI was well-calibrated, with good agreement between observed and predicted risk. Compared with the medium-risk group (deciles 3-8), the high-risk group (deciles 9, 10) had 3.5-fold (hazard ratio, 3.5; 95% CI, 2.4-5.1) higher risk of HCC. THCC-RI had similar discrimination as the Age, Male, Albumin-bilirubin, and Platelets (aMAP) score during the first 2 years of follow-up, but the areas under the receiver operating characteristic curve for aMAP dropped more than those for THCC-RI as the time horizon expanded beyond 3 years.
In an independent multi-center cohort, THCC-RI had good performance for predicting the future risk of HCC in patients with cirrhosis, with stable discrimination and calibration over a 5-year follow-up. Implementation of THCC-RI into clinical care pathways requires further research.

PMID:
41672261
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.